Anti-Urolithiatic Activity of Silver Nanoparticles of Terminalia Chebula Bark

The potential inhibitory action of herbals plays an indispensable role in modern medicine. The struvite crystal is an infectious stone related to urinary tract infection, hence the present study highlighted the anti-urolithiatic potential of Terminalia chebula bark mediated silver nanoparticles. Sil...

Full description

Saved in:
Bibliographic Details
Published in:Oriental journal of chemistry 2021-02, Vol.37 (1), p.109-115
Main Authors: Vidhya, S., Rose, A. Leema, Priya, F. Janeeta, Keerthana, T., Priyadharshini, R.
Format: Article
Language:English
Subjects:
Crystals
Fourier transforms
Infrared spectroscopy
Medical research
Nanoparticles
Particle size
Phenols
Phytochemicals
Quantitative analysis
Silver
Spectrum analysis
Steroids
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The potential inhibitory action of herbals plays an indispensable role in modern medicine. The struvite crystal is an infectious stone related to urinary tract infection, hence the present study highlighted the anti-urolithiatic potential of Terminalia chebula bark mediated silver nanoparticles. Silver nanoparticles formation was confirmed by SPR band at 437nm. FT-IR spectroscopic studies suggested that phytoconstituents are primarily responsible for the reduction and capping of silver nanoparticles. TEM and XRD analysis revealed that the uniformity in shape and crystalline nature of T. chebula mediated silver nanoparticles. The single gel diffusion method was adopted to found the inhibition action of T.chebula mediated silver nanoparticles in struvite crystals. The inhibition efficiency was found to be 87.9 %, indicated that T. chebula mediated silver nanoparticles was a good inhibitor for the struvite crystals. The shift in band values of FTIR spectra confirms that the phyto constituents present in T. chebula bark is responsible for the anti-urolithiatic activity.
ISSN:0970-020X
2231-5039
DOI:10.13005/ojc/370114